Document is current
Any future updates will be listed below
-
Authors
Rudà, Roberta https://orcid.org/0000-0001-9134-1537
Horbinski, Craig https://orcid.org/0000-0001-8340-9992
van den Bent, Martin https://orcid.org/0000-0001-5710-5127
Preusser, Matthias https://orcid.org/0000-0003-3541-2315
Soffietti, Riccardo https://orcid.org/0000-0002-9204-7038
- License Information
-
More Information
Article History
Accepted: 26 April 2024
First Online: 17 May 2024
Competing interests
: R.R. has received honoraria for lectures from UCB, Servier, Genenta, Novocure and Curevac. M.v.d.B. reports consulting for Boehringer Ingelheim, F. Hoffman-La Roche, Fore Biotherapeutics, Genenta, Incyte Corporation, AnHeart therapeutics, Mundipharma, SymBio Pharma and Servier Affaires Medicales. M.P. has received honoraria for lectures, consultation or advisory board participation from Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, BMJ Journals, MedMedia, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dome, Tocagen, Adastra, Gan & Lee Pharmaceuticals, Janssen, Servier, Miltenyi, Böhringer Ingelheim and Telix, Medscape. R.S. has received honoraria for lectures, consultation or advisory board participation from Celldex Therapeutics, Mundipharma, Puma Technology, Astra Zeneca, Servier and Seagen. C.H. declares no competing interests.
